Forest Pharmaceuticals, Inc. DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

Related Companies

On July 1, 2014, Actavis (NYSE:ACT) completed the acquisition of Forest Laboratories, creating one of the world’s fastest-growing specialty pharmaceutical companies with annual revenues of more than $15 billion anticipated for 2015. The combination of Actavis and Forest creates a new breed of specialty pharmaceutical company, with size and scale, a balanced offering of strong brands and generics, a focus on strategic, lower...

On July 1, 2014, Actavis (NYSE:ACT) completed the acquisition of Forest Laboratories, creating one of the world’s fastest-growing specialty pharmaceutical companies with annual revenues of more than $15 billion anticipated for 2015. The combination of Actavis and Forest creates a new breed of specialty pharmaceutical company, with size and scale, a balanced offering of strong brands and generics, a focus on strategic, lower-risk drug development and a flexible, scalable business model that permits it to adapt quickly to ever-changing industry dynamics and drive sustainable, long-term organic growth. World-Class Brands Business The new Actavis (NYSE:ACT) has a world-class brands business competing across multiple market segments. On a pro forma combined basis for full year 2014, Actavis’ brand pharmaceutical business now includes an approximately $2 billion CNS franchise; Gastroenterology (GI) and Women's Health franchises valued at approximately $1 billion each; a Cardiovascular franchise that generates approximately $500 million; and Urology and Dermatology/Established Brand franchises approaching $500 million a year in sales each; as well as emerging and sustainable portfolios in the Infectious Disease and Respiratory therapeutic categories. Our key marketed brands include BYSTOLIC® (nebivolol), DALIRESP® (roflumilast), FETZIMA® (levomilnacipran extended-release capsules), LINZESS® (linaclotide), NAMENDA® (memantine HCl), NAMENDA XR® (memantine HCl), SAPHRIS® (asenapine), SAVELLA® (milnacipran HCl), TEFLARO® (ceftaroline fosamil) for injection, TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder), and VIIBRYD® (vilazodone HCl). $1+ Billion Annual Investment in R&D Actavis invests more than $1 billion annually in the development of distinctive brand and generic products. This commitment is driven by one of the strongest development-focused R&D organizations in the industry, with an emphasis on strategic, innovative development of important durable products that will drive long-term value, and on being the partner of choice for new and existing development collaborations. Built on Integrity Actavis proudly and actively promotes professional behavior and personal integrity in every aspect of our business operations. We want to be known both as a resourceful innovator and as a global competitor. However, in matters of integrity there is no room for flexibility or creativity. In everything we do, we expect absolute compliance with the highest ethical standards.

Company profile for Forest Laboratories, Inc.

Forest Pharmaceuticals, Inc.

FOREST PHARMACEUTICALS, INC.

About

Contact Details

EVENTS

Webinars & Exhibitions

PRESENTATION(s)

VIDEO(s)

DIGITAL CONTENT

40 News

APIs // Active Pharmaceutical Ingredients

21 APIs

21 USDMF

DEVELOPMENTS

DOSSIERs // Finished Dosage Formulations

64 Dossiers

61 FDA Orange Book

3 Europe

EXCIPIENTS

1 Regulatory Filings

1 USDMF

INSPECTIONS & REGISTRATIONS

17 FDA

6 EDQM

What are you looking for?